Valuation of early-stage drug candidates taking into account investments, risks and market sizes
Masterarbeit, Studienarbeit, Diplomarbeit
This thesis will be performed in collaboration with InterAx Biotech AG, Switzerland. Overall, the goal of this thesis is to research and define basic assumptions for drug discovery costs, risks, and market sizes for given medical indications. In addition, the risk-adjusted net present value (rNPV)* should be calculated at different stages with previously acquired data and compared with other valuation methods.
In order to be able to reach the required objectives, prior knowledge of quantitative finance and a strong interest in the pharmaceutical industry are advantageous when choosing this topic.
Please contact Prof. Dr. Carolin Bock briefly explaining your motivation with CV current transcript of records
*Reference: Stewart et al.: Putting a price on biotechnology. Nature Biotechnology, 2001